420 related articles for article (PubMed ID: 24604006)
21. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
Darmopil S; Muñetón-Gómez VC; de Ceballos ML; Bernson M; Moratalla R
Eur J Neurosci; 2008 Feb; 27(3):580-92. PubMed ID: 18279311
[TBL] [Abstract][Full Text] [Related]
22. Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra.
Knyihár-Csillik E; Chadaide Z; Mihály A; Krisztin-Péva B; Fenyo R; Vécsei L
Acta Neuropathol; 2006 Aug; 112(2):127-37. PubMed ID: 16788821
[TBL] [Abstract][Full Text] [Related]
23. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
24. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease.
Depino AM; Earl C; Kaczmarczyk E; Ferrari C; Besedovsky H; del Rey A; Pitossi FJ; Oertel WH
Eur J Neurosci; 2003 Nov; 18(10):2731-42. PubMed ID: 14656322
[TBL] [Abstract][Full Text] [Related]
25. Exogenous l-DOPA induce no dopamine immuno-reactivity in striatal astroglias and microglias of adult rats with extensive nigro-striatal dopaminergic denervation.
Maeda T; Nagata K; Yoshida Y
Neurosci Lett; 2008 Mar; 433(3):255-8. PubMed ID: 18255227
[TBL] [Abstract][Full Text] [Related]
26. Neuroprotective properties of mildronate, a small molecule, in a rat model of Parkinson's disease.
Klusa VZ; Isajevs S; Svirina D; Pupure J; Beitnere U; Rumaks J; Svirskis S; Jansone B; Dzirkale Z; Muceniece R; Kalvinsh I; Vinters HV
Int J Mol Sci; 2010 Nov; 11(11):4465-87. PubMed ID: 21151450
[TBL] [Abstract][Full Text] [Related]
27. Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions.
Machado-Filho JA; Correia AO; Montenegro AB; Nobre ME; Cerqueira GS; Neves KR; Naffah-Mazzacoratti Mda G; Cavalheiro EA; de Castro Brito GA; de Barros Viana GS
Behav Brain Res; 2014 May; 264():116-25. PubMed ID: 24525422
[TBL] [Abstract][Full Text] [Related]
28. A potential target for the treatment of Parkinson's disease: effect of lateral habenula lesions.
Han B; Jin HJ; Song MY; Wang T; Zhao H
Parkinsonism Relat Disord; 2014 Nov; 20(11):1191-5. PubMed ID: 25219971
[TBL] [Abstract][Full Text] [Related]
29. Further Characterization of Intrastriatal Lipopolysaccharide Model of Parkinson's Disease in C57BL/6 Mice.
Deng I; Corrigan F; Garg S; Zhou XF; Bobrovskaya L
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299000
[TBL] [Abstract][Full Text] [Related]
30. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease.
Decressac M; Pain S; Chabeauti PY; Frangeul L; Thiriet N; Herzog H; Vergote J; Chalon S; Jaber M; Gaillard A
Neurobiol Aging; 2012 Sep; 33(9):2125-37. PubMed ID: 21816512
[TBL] [Abstract][Full Text] [Related]
31. Anti-Inflammatory Modulation of Microglia via CD163-Targeted Glucocorticoids Protects Dopaminergic Neurons in the 6-OHDA Parkinson's Disease Model.
Tentillier N; Etzerodt A; Olesen MN; Rizalar FS; Jacobsen J; Bender D; Moestrup SK; Romero-Ramos M
J Neurosci; 2016 Sep; 36(36):9375-90. PubMed ID: 27605613
[TBL] [Abstract][Full Text] [Related]
32. Neuroprotective and behavioural assessments of an imidazolium compound (DBZIM) in a rat model of Parkinson's disease induced by 6-OHDA.
Chan HH; Kumar S; Zhuo L
Eur J Pharmacol; 2013 Sep; 715(1-3):405-13. PubMed ID: 23652161
[TBL] [Abstract][Full Text] [Related]
33. Complex Changes in the Innate and Adaptive Immunity Accompany Progressive Degeneration of the Nigrostriatal Pathway Induced by Intrastriatal Injection of 6-Hydroxydopamine in the Rat.
Ambrosi G; Kustrimovic N; Siani F; Rasini E; Cerri S; Ghezzi C; Dicorato G; Caputo S; Marino F; Cosentino M; Blandini F
Neurotox Res; 2017 Jul; 32(1):71-81. PubMed ID: 28285346
[TBL] [Abstract][Full Text] [Related]
34. Ameliorating effects of curcumin on 6-OHDA-induced dopaminergic denervation, glial response, and SOD1 reduction in the striatum of hemiparkinsonian mice.
Tripanichkul W; Jaroensuppaperch EO
Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1360-8. PubMed ID: 23740450
[TBL] [Abstract][Full Text] [Related]
35. Quantitative analyses of GFRalpha-1 and GFRalpha-2 mRNAs and tyrosine hydroxylase protein in the nigrostriatal system reveal bilateral compensatory changes following unilateral 6-OHDA lesions in the rat.
Kozlowski DA; Miljan EA; Bremer EG; Harrod CG; Gerin C; Connor B; George D; Larson B; Bohn MC
Brain Res; 2004 Aug; 1016(2):170-81. PubMed ID: 15246853
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic effects of fucoidan in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: Role of NADPH oxidase-1.
Zhang FL; He Y; Zheng Y; Zhang WJ; Wang Q; Jia YJ; Song HL; An HT; Zhang HB; Qian YJ; Tong YL; Dong L; Wang XM
CNS Neurosci Ther; 2014 Dec; 20(12):1036-44. PubMed ID: 25399812
[TBL] [Abstract][Full Text] [Related]
37. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
[TBL] [Abstract][Full Text] [Related]
38. Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons.
Frau L; Morelli M; Simola N
Exp Neurol; 2013 Sep; 247():663-72. PubMed ID: 23499830
[TBL] [Abstract][Full Text] [Related]
39. Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease.
Ye M; Wang XJ; Zhang YH; Lu GQ; Liang L; Xu JY; Chen SD
Brain Res; 2007 Apr; 1142():206-16. PubMed ID: 17336273
[TBL] [Abstract][Full Text] [Related]
40. The effects of unilateral 6-OHDA lesion in medial forebrain bundle on the motor, cognitive dysfunctions and vulnerability of different striatal interneuron types in rats.
Ma Y; Zhan M; OuYang L; Li Y; Chen S; Wu J; Chen J; Luo C; Lei W
Behav Brain Res; 2014 Jun; 266():37-45. PubMed ID: 24613235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
